143 related articles for article (PubMed ID: 38723202)
1. Improving our understanding on the clinical role of plasmin-mediated von Willebrand factor degradation.
Otmani HE; Vanhoorelbeke K; Tersteeg C
Curr Opin Hematol; 2024 May; ():. PubMed ID: 38723202
[TBL] [Abstract][Full Text] [Related]
2. Plasmin-cleaved von Willebrand factor as a biomarker for microvascular thrombosis.
El Otmani H; Frunt R; Smits S; Barendrecht AD; de Maat S; Fijnheer R; Lenting PJ; Tersteeg C
Blood; 2024 May; 143(20):2089-2098. PubMed ID: 38271661
[TBL] [Abstract][Full Text] [Related]
3. Plasmin Cleaves Von Willebrand Factor at K1491-R1492 in the A1-A2 Linker Region in a Shear- and Glycan-Dependent Manner In Vitro.
Brophy TM; Ward SE; McGimsey TR; Schneppenheim S; Drakeford C; O'Sullivan JM; Chion A; Budde U; O'Donnell JS
Arterioscler Thromb Vasc Biol; 2017 May; 37(5):845-855. PubMed ID: 28279966
[TBL] [Abstract][Full Text] [Related]
4. Proteolytic inactivation of ADAMTS13 by plasmin in human plasma: risk of thrombotic thrombocytopenic purpura.
Shin Y; Miyake H; Togashi K; Hiratsuka R; Endou-Ohnishi K; Imamura Y
J Biochem; 2018 May; 163(5):381-389. PubMed ID: 29228282
[TBL] [Abstract][Full Text] [Related]
5. Truncation of ADAMTS13 by Plasmin Enhances Its Activity in Plasma.
Clark CC; Mebius MM; de Maat S; Tielens AGM; de Groot PG; Urbanus RT; Fijnheer R; Hazenberg BPC; van Hellemond JJ; Maas C
Thromb Haemost; 2018 Mar; 118(3):471-479. PubMed ID: 29534248
[TBL] [Abstract][Full Text] [Related]
6. Plasmin cleavage of von Willebrand factor as an emergency bypass for ADAMTS13 deficiency in thrombotic microangiopathy.
Tersteeg C; de Maat S; De Meyer SF; Smeets MW; Barendrecht AD; Roest M; Pasterkamp G; Fijnheer R; Vanhoorelbeke K; de Groot PG; Maas C
Circulation; 2014 Mar; 129(12):1320-31. PubMed ID: 24449821
[TBL] [Abstract][Full Text] [Related]
7. Effects of Plasmin on von Willebrand Factor and Platelets: A Narrative Review.
van der Vorm LN; Remijn JA; de Laat B; Huskens D
TH Open; 2018 Apr; 2(2):e218-e228. PubMed ID: 31249945
[TBL] [Abstract][Full Text] [Related]
8. [ADAMTS13-Mediated Proteolytic Cleavage of Unusually Large von Willebrand Factor Polymers on Endothelial Cells in the Absence of Fluid Shear Stress].
Zhao SC; Li H; Wang M; Zhao YH; Li XJ; Jin SY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Apr; 32(2):532-540. PubMed ID: 38660863
[TBL] [Abstract][Full Text] [Related]
9. Effects of plasmin on von Willebrand factor multimers. Degradation in vitro and stimulation of release in vivo.
Hamilton KK; Fretto LJ; Grierson DS; McKee PA
J Clin Invest; 1985 Jul; 76(1):261-70. PubMed ID: 3160727
[TBL] [Abstract][Full Text] [Related]
10. The Intriguing Relationships of von Willebrand Factor, ADAMTS13 and Cardiac Disease.
Reardon B; Pasalic L; Favaloro EJ
J Cardiovasc Dev Dis; 2021 Sep; 8(9):. PubMed ID: 34564132
[TBL] [Abstract][Full Text] [Related]
11. Apolipoprotein B100/Low-Density Lipoprotein Regulates Proteolysis and Functions of von Willebrand Factor under Arterial Shear.
Cao W; Abdelgawwad MS; Li J; Zheng XL
Thromb Haemost; 2019 Dec; 119(12):1933-1946. PubMed ID: 31493779
[TBL] [Abstract][Full Text] [Related]
12. Control of von Willebrand factor multimer size and implications for disease.
Pimanda J; Hogg P
Blood Rev; 2002 Sep; 16(3):185-92. PubMed ID: 12163004
[TBL] [Abstract][Full Text] [Related]
13. An Overview of Laboratory Testing for ADAMTS13.
Favaloro EJ; Pasalic L
Methods Mol Biol; 2023; 2663():481-486. PubMed ID: 37204731
[TBL] [Abstract][Full Text] [Related]
14. Removal of the C-Terminal Domains of ADAMTS13 by Activated Coagulation Factor XI induces Platelet Adhesion on Endothelial Cells under Flow Conditions.
Garland KS; Reitsma SE; Shirai T; Zilberman-Rudenko J; Tucker EI; Gailani D; Gruber A; McCarty OJT; Puy C
Front Med (Lausanne); 2017; 4():232. PubMed ID: 29326937
[TBL] [Abstract][Full Text] [Related]
15. Higher and lower active circulating VWF levels: different facets of von Willebrand disease.
Casonato A; Pontara E; Morpurgo M; Sartorello F; De Groot PG; Cattini MG; Daidone V; De Marco L
Br J Haematol; 2015 Dec; 171(5):845-53. PubMed ID: 26456374
[TBL] [Abstract][Full Text] [Related]
16. ADAMTS13 inhibition to treat acquired von Willebrand syndrome during mechanical circulatory support device implantation.
Deconinck SJ; Nix C; Barth S; Bennek-Schöpping E; Rauch A; Schelpe AS; Roose E; Feys HB; Pareyn I; Vandenbulcke A; Muia J; Vandenbriele C; Susen S; Meyns B; Tersteeg C; Jacobs S; De Meyer SF; Vanhoorelbeke K
J Thromb Haemost; 2022 Dec; 20(12):2797-2809. PubMed ID: 36128768
[TBL] [Abstract][Full Text] [Related]
17. Update on von Willebrand factor multimers: focus on high-molecular-weight multimers and their role in hemostasis.
Stockschlaeder M; Schneppenheim R; Budde U
Blood Coagul Fibrinolysis; 2014 Apr; 25(3):206-16. PubMed ID: 24448155
[TBL] [Abstract][Full Text] [Related]
18. Amplified endogenous plasmin activity resolves acute thrombotic thrombocytopenic purpura in mice.
Tersteeg C; Joly BS; Gils A; Lijnen R; Deckmyn H; Declerck PJ; Plaimauer B; Coppo P; Veyradier A; Maas C; De Meyer SF; Vanhoorelbeke K
J Thromb Haemost; 2017 Dec; 15(12):2432-2442. PubMed ID: 28981198
[TBL] [Abstract][Full Text] [Related]
19. Proteolytic resistance conferred to fibrinogen by von Willebrand factor.
Tanka-Salamon A; Kolev K; Machovich R; Komorowicz E
Thromb Haemost; 2010 Feb; 103(2):291-8. PubMed ID: 20024497
[TBL] [Abstract][Full Text] [Related]
20. Mutation G1629E Increases von Willebrand Factor Cleavage via a Cooperative Destabilization Mechanism.
Aponte-Santamaría C; Lippok S; Mittag JJ; Obser T; Schneppenheim R; Baldauf C; Gräter F; Budde U; Rädler JO
Biophys J; 2017 Jan; 112(1):57-65. PubMed ID: 28076816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
